Search Results
Feb 03, 2026, 06:30 ET Presbyterian Healthcare Services Expands Use of GW RhythmX to 200 Primary Care Clinicians in the First Full System Deployment of a Precision Care AI Platform
value-based arrangements. Within weeks of launching the initial pilot, the platform helped clinicians identify and review over 200 combined HCC and non-HCC conditions across more than 10,000 patient encounters. Clinicians reported that tasks previously requiring extensive manual chart review could
More news about: GW RhythmX
Feb 02, 2026, 17:31 ET TIGIT Inhibitors Market Poised for Strong Growth Through 2034, Driven by Expanding Immuno-Oncology Pipeline | DelveInsight
combination with atezolizumab and bevacizumab as first-line treatment in patients with untreated locally advanced or metastatic Hepatocellular Carcinoma (HCC).What are TIGIT Inhibitors?TIGIT inhibitors are a class of cancer immunotherapy agents designed to enhance the body's immune
More news about: DelveInsight Business Research, LLP
Feb 02, 2026, 10:45 ET Surety Market to Surpass US$ 33.1 Billion by 2032, Reveals Global Surety Bond Industry Analysis and Growth Trends: Maximize Market Research
Ltd. 20. Arch Insurance Group 21. Coface 22. Swiss Re 23. AoN 24. Zurich Insurance Group 25. Tokio Marine HCC 26. AXA XL 27. QBE Insurance Group Limited 28. Intact US Insurance 29. Berkshire Hathaway Specialty Insurance 30.
More news about: Maximize Market Research Pvt. Ltd.
Jan 27, 2026, 03:18 ET Libevitug Approved in China as First-in-Class Treatment for Hepatitis D
mono-infection, co-infection with HBV and HDV significantly increases—often doubling—the risk of developing liver cirrhosis, hepatocellular carcinoma (HCC), requiring liver transplantation, and liver-related mortality, making it the most severe known form of chronic viral hepatitis. According to the WHO,
More news about: Huahui Health Ltd.
Jan 21, 2026, 10:12 ET Improving Academic Pathways: Workcred Releases Resources for Community Colleges
Houston City College, which provides examples of the institutional policies and processes that HCC developed or refined, and how they were implemented to align with changes in Texas policy. For example, HCC created 24 for-credit and 21 non-credit continuing education credentials for students seeking to
More news about: Workcred
Jan 20, 2026, 09:00 ET Reveleer Announces EVE™ Hybrid AI: A New Approach to Delivering Provable, Explainable, and Scalable Diagnosis Suspecting
claims, and FHIR filesA clinician-authored prospective suspecting engine applying more than 3,300 deterministic clinical rules across multiple HCC modelsA traceable, audit-ready evidence graph linking every suspect to exact source documentationRapid, auditable updates to clinical
More news about: Reveleer
Jan 18, 2026, 19:30 ET AbelZeta Announces Remaining China Rights to GPC3 Armored CAR-T Therapy to be Acquired by AstraZeneca
being investigated for the treatment of HCC and other solid tumors.About HCCLiver cancer is the third-leading cause of cancer death and the sixth most commonly diagnosed cancer worldwide. Several types of primary liver cancer occur in adults, HCC being the most common form. About 75%
More news about: AbelZeta Pharma, Inc.
Jan 15, 2026, 10:25 ET Accuity Delivers $800M+ in Cash Benefit to Clients in 2025
delivered. The company's proven, AI-first approach delivers the highest ROI, improves quality metrics such as Case Mix Index (CMI) and HCC capture, and builds lasting confidence in clinical and financial performance. For more information, visit
More news about: Accuity
Jan 12, 2026, 20:44 ET Oricell Therapeutics Announces US$70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies
across multiple pipeline CAR-T products. Its lead program, Ori-C101, is an autologous GPC3-targeted CAR-T therapy for advanced hepatocellular carcinoma (HCC). Both a Phase I Investigator-Initiated Trial (IIT) and a Phase I IND study of Ori-C101 are completed. With far-leading-industry efficacy and safety
More news about: OriCell Therapeutics Co., Ltd.
Jan 12, 2026, 08:05 ET PENGUIN AI LAUNCHES HCC CODING & RISK ADJUSTMENT SOLUTION AS SNOWFLAKE NATIVE APP ON SNOWFLAKE MARKETPLACE
greater accuracy while reducing compliance risk. They can also transform HCC coding from a bottleneck into a competitive advantage."Payers and risk-bearing providers are under increasing pressure to ensure accurate, defensible HCC documentation," said Fawad Butt, CEO of Penguin Ai. "By bringing Penguin
More news about: Penguin Ai
Dec 16, 2025, 05:59 ET Breakthrough Progress: METiS TechBio Publishes Consecutive Research Findings in Nature Communications and the Journal for ImmunoTherapy of Cancer
hepatocellular carcinoma (HCC), delivered via METiS's proprietary liver-targeted LNP system. Study results demonstrate that, once delivered to and taken up within the liver, the mRNA is translated in situ and secreted locally as high level of bispecific antibodies, which rapidly penetrate HCC tissues. Employing
More news about: METiS TechBio
Dec 15, 2025, 09:00 ET Helio Genomics Forms Strategic Partnership with LiverRight Aimed at Broadening Nationwide Access to Early Liver Cancer Detection
under-diagnosed, and patients often face months-long delays to see a specialist."This partnership represents a new standard in hepatocellular carcinoma (HCC) care," said Dr. Bharat Tewarie, Chief Executive Officer of Helio Genomics. "When it comes to liver cancer, every week matters—delays in diagnosis can
More news about: Helio Genomics
Dec 09, 2025, 08:00 ET CREATE Medicines Doses First Patient in Frontline HCC Trial Evaluating MT-303, an In Vivo CAR Therapy, in Combination with Standard-of-Care Immunotherapy
carcinoma (HCC) clinical trial evaluating MT-303. The study is assessing MT-303, an investigational in vivo GPC3-targeted CAR therapy delivered by the company's proprietary mRNA-LNP platform, in combination with atezolizumab and bevacizumab, the current global standard-of-care regimen for frontline HCC.
More news about: CREATE Medicines, Inc.
Dec 08, 2025, 08:30 ET Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting
translational rationale for the initiation of a Phase 1/2 clinical trial of the combination of standard of care regorafenib with the SCD1 inhibitor Aramchol in HCC and other GI cancers. Once a recommended Phase 2 dose is found, Galmed plans to add a dose expansion cohort that will include Metformin and will evaluate
More news about: Galmed Pharmaceuticals Ltd.
Dec 04, 2025, 08:32 ET J & D Pharmaceuticals LLC Receives Orphan Drug Designation for Treatment of Hepatocellular Carcinoma (HCC)
Carcinoma (HCC) a rare and life-threatening disorder that is estimated to occur in approximately 73,000 individuals in the United States in 2025. HCC is a devastating disorder that has a very poor prognosis. With FDA approved medications the amount of time extended in patient with HCC is only 2.5
More news about: J & D Pharmaceuticals LLC
Dec 01, 2025, 08:30 ET Galmed Issues CEO Letter to Shareholders
resistance.These results support our plans to advance Aramchol into a Phase 1/2 clinical trial for metastatic colorectal cancer (CRC), hepatocellular carcinoma (HCC), and cholangiocarcinoma in collaboration with VCU Massey Comprehensive Cancer Center in early 2026.Based on this approach, we are currently
More news about: Galmed Pharmaceuticals Ltd.
Nov 26, 2025, 10:16 ET Stop loss insurance Market to Reach $26.9 billion by 2024 in the short term and $113.5 billion by 2034 Globally, at 15.1% CAGR: Allied Market Research
HM insurance group, Berkshire Hathaway Specialty Insurance, Nationwide Mutual Insurance Company, Sun Life Assurance Company of Canada, Tokio Marine HCC, BCS Financial Corporation, Swiss Re., Voya Financial, Liberty Mutual Insurance Company, Cigna Healthcare, Berkley Accident and Health, QBE Holdings,
More news about: Allied Market Research
Nov 20, 2025, 10:32 ET Greenway Health® Reimagines the Future of Ambulatory Care, Unveils The Automated Healthcare Practice™ at ENGAGE 2025
begins this December with the launch of Greenway Clinical Assist 3.0, empowering practices with AI-powered documentation, intelligent chart search, and HCC coding assistance that free clinicians to focus on care. This isn't a preview—it's progress. Practices adopting Clinical Assist
More news about: Greenway Health
Nov 18, 2025, 09:00 ET Azara Healthcare Releases New Risk Adjustment Capabilities in EHR Plug-In for athenaOne via the athenahealth Marketplace
athenahealth's electronic health records (EHR) product. This new capability enables providers to efficiently identify and address diagnosis coding gaps, both Medicare/HCC and Medicaid, during patient visits—reducing administrative burden, improving documentation accuracy, and driving stronger performance in value-based
More news about: Azara Healthcare
Nov 18, 2025, 07:00 ET XpertDox Partners with CHP Berkshires to Improve Revenue Cycle Performance through AI-Powered Medical Coding
collaboration aims to revolutionize CHP Berkshires' revenue cycle operations, improve coding quality scores, focus on value-based care initiatives, ensure HCC recapture, and ensure compliance with Medicare's FQHC coding and billing standards.
More news about: XpertDox
Nov 17, 2025, 08:30 ET Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro
of Aramchol and Stivarga® is expected to enter phase 1b clinical trials early 2026 in metastatic colorectal cancer (CRC), hepatocellular (HCC) and cholangiocarcinoma patients with a planned expansion cohort including metformin.
More news about: Galmed Pharmaceuticals Ltd.
Nov 13, 2025, 03:42 ET Apollo Hospitals Achieves Historic Milestone: Completes 5,000 Liver Transplants, Sets a New Benchmark for Indian and South Asian Healthcare
access timely, world-class liver transplantation — the gold standard treatment for end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC) — strengthening Apollo's leadership in transplant medicine across India, Asia, and the world.
More news about: Apollo Hospitals
Nov 05, 2025, 16:07 ET Precision Biologics to Reveal Preclinical Efficacy of Novel Tumor-Specific ADC against multiple human cancer types at SITC 2025
in vitro cytotoxicity of PB-vc-MMAE-5 was evaluated in 9 human cancer cell lines, including prostate (PC-3, LnCAP), triple negative breast (HCC1937, MDA-MB-231), ER+,PR+,HER2+ breast (BT-474), squamous cell carcinoma of the lung (NCI-H226), ovarian (OV-90), colorectal (SW403), and pancreatic (CFPAC-1)
More news about: Precision Biologics
Nov 05, 2025, 16:05 ET Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights
Advanced Phase 1 HCC Study – SURF431. TYRA-430 is an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers. The SURF431 study continues to enroll and dose adults with hepatocellular carcinoma (HCC) and other solid tumors with activating
More news about: Tyra Biosciences
Nov 05, 2025, 10:45 ET The global travel insurance market size was valued at $23.8 billion in 2024, and is projected to reach $132.9 billion by 2034, growing at a CAGR of 18.4% from 2025 to 2034
insurance market include Chubb Limited, Staysure, Just Travel Cover, AXA, Allianz, Aviva Plc, Berkshire Hathaway Specialty Insurance, Tokio Marine HCC., HDFC ERGO General Insurance Company Limited, The Manufacturers Life Insurance Company, Income Insurance Limited, MSIG Insurance (Singapore) Pte. Ltd,
More news about: Allied Market Research